CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc.
(GNS) today announced that it has entered into an agreement with Biogen
Idec under which GNS will use its proprietary REFS(TM) software platform to
process clinical data provided by Biogen Idec to identify targets and
biomarkers in inflammation. A forward simulation model generated directly
from the Biogen Idec data will be licensed to Biogen Idec at the conclusion
of this project. Financial terms of the agreement were not disclosed.
GNS employs massively parallel supercomputers to probe vast amounts of
raw human biological data to discover new insights into the biological
causes of human disease, and new opportunities for diagnosis and treatment.
Under this agreement, GNS will use its REFS(TM) (Reverse
Engineering/Forward Simulation) platform to transform genetic, genomic, and
clinical data provided by Biogen Idec to generate and score billions of
hypotheses to discover new drug targets and biomarkers rapidly.
"Our proprietary technology is capable of taking raw 'omic' data and
running billions of calculations in a short period of time to find
potential biomarkers and promising drug targets that could lead to more
effective patient treatments," said Colin Hill, CEO of GNS. "It is the
value and speed of our REFS(TM) technology and the potential it offers to
the Biogen Idec drug development program that forged our partnership."
About REFS(TM)
Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that
systematically turns multiple layers of biologically relevant data into an
unprecedented view of human biology and disease as a "whole." REFS(TM)
begins with raw biological data (genetic, genomic, epigenetic, proteomic,
metabolomic and environmental) and rapidly performs billions upon billions
of calculations to determine how the molecules interact with one another in
the complete system (Reverse Engineering). These computer-assembled models
are then queried rapidly through billions of in silico experiments (Forward
Simulation) to discover the highest-impact molecular targets for the
disease being studied and the corresponding efficacy and toxicity markers
related to specific drug treatments. These findings are then tested in both
the laboratory and the clinic, enabling a faster, more focused and more
effective drug discovery and development process.
About Gene Network Sciences
Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com/) is
a leader in biosimulation with its ability to derive molecular mechanisms
of drugs and diseases directly from molecular profiling and clinical data
without any a priori knowledge. Headquartered in Cambridge, Massachusetts,
GNS uses its REFS(TM) (reverse engineering and forward simulation)
technology in pharmaceutical and clinical settings to rapidly turn complex
and heterogeneous data sets into cell and organ-level computer models of
disease biology, drug efficacy and drug safety. These models simulate
mechanisms of disease and the clinical performance of drug candidates. By
discovering how and why specific drug candidates impact human biology, GNS
technology enables the rapid development of breakthrough drug and
diagnostic products.
For more Information, please contact:
Lynn Blenkhorn Thomas Neyarapally
Feinstein Kean Healthcare Gene Network Sciences, Inc.
508-851-0930 617-494-0492
Lynn.blenkhorn@fkhealth.com tneyarapally@gnsbiotech.com
SOURCE Gene Network Sciences, Inc.
 back to top
Related links:
http://www.gnsbiotech.com
CONTACT:
Lynn Blenkhorn of Feinstein Kean Healthcare,
+1-508-851-0930, Lynn.blenkhorn@fkhealth.com; or Thomas
Neyarapally of Gene Network Sciences, Inc., +1-617-494-0492,
tneyarapally@gnsbiotech.com
|
